QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) All Versions of this Article: jpet.103.051961v1 306/3/1077    most recent Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Kaplan, B. L. F. Articles by Kaminski, N. E. Search for Related Content PubMed PubMed Citation Articles by Kaplan, B. L. F. Articles by Kaminski, N. E.

INFLAMMATION AND IMMUNOPHARMACOLOGY

Evidence for Cannabinoid Receptor-Dependent and -Independent Mechanisms of Action in Leukocytes

Department of Pharmacology and Toxicology and National Food Safety and Toxicology Center, Michigan State University, East Lansing, Michigan

Cannabinoids exhibit immunosuppressive actions that include inhibition of interleukin-2 production in response to a variety of T cell activation stimuli. Traditionally, the effects of these compounds have been attributed to cannabinoid receptors CB1 and CB2, both of which are expressed in mouse splenocytes. Therefore, N-(piperidin-1-yl)-5-(4-chlorophenyl)-1-(2,4-dichlorphenyl)-4-methyl-H-pyrazole-3 carboxyamidehydrochloride (SR141716A), a CB1 antagonist, and N-[(1S)-endo-1,3,3,-trimethyl-bicyclo[2,2,1]heptan-2-yl]-5-(4-chloro-3-methylphenyl)-1-(4-methylbenzyl)-pyrazole-3-carboxamide (SR144528), a CB2 antagonist, were used to investigate the role of cannabinoid receptors in the cannabinoid-induced inhibition of phorbol ester plus calcium ionophore (PMA/Io)-stimulated interleukin-2 production by mouse splenocytes. PMA/Io-stimulated interleukin-2 production was inhibited by cannabinol, cannabidiol, and both WIN 55212-2 stereoisomers with a rank order potency of R-(+)-[2,3-dihydro-5-methyl-3-[(morpholinyl)methyl]pyrrolo[1,2,3-de]-1,4-benzoxazinyl]-(1-napthanlenyl) methanone mesylate (WIN 55212-2) cannabidiol > S-(-)-[2,3-dihydro-5-methyl-3-[(morpholinyl)methyl]pyrrolo[1,2,3-de]-1,4-benzoxazinyl]-(1-napthanlenyl) methanone mesylate (WIN 55212-3) cannabinol. Cannabinoid-induced inhibition of PMA/Io-stimulated interleukin-2 was not attenuated by the presence of both SR144528 and SR141716A. Using pertussis toxin to address the role of G protein-coupled receptors in this response, it was determined that pertussis toxin treatment did not attenuate cannabinol-induced inhibition of PMA/Io-stimulated interleukin-2. With the demonstration that cannabinoid-induced inhibition of PMA/Io-stimulated interleukin-2 was not mediated via CB1 or CB2, alternative targets of cannabinoids in T cells were examined. Specifically, it was demonstrated that cannabinoids elevated intracellular calcium concentration in resting splenocytes and that the cannabinol-induced elevation in intracellular calcium concentration was attenuated by treatment with both SR144528 and SR141716A. Interestingly, pretreatment of splenocytes with agents that elevate intracellular calcium concentration inhibited PMA/Io-stimulated interleukin-2 production, suggesting that an elevation in intracellular calcium concentration might be involved in the mechanism of interleukin-2 inhibition. These studies suggest that immune modulation produced by cannabinoids involves multiple mechanisms, which might be both cannabinoid receptor-dependent and -independent.

Address correspondence to: Dr. Norbert E. Kaminski, Department of Pharmacology and Toxicology, 315 National Food Safety and Toxicology Center, Michigan State University, East Lansing, MI 48824. E-mail: kamins11{at}msu.edu

This article has been cited by other articles:

				A. E. B. Springs, P. W. F. Karmaus, R. B. Crawford, B. L. F. Kaplan, and N. E. Kaminski Effects of targeted deletion of cannabinoid receptors CB1 and CB2 on immune competence and sensitivity to immune modulation by {Delta}9-tetrahydrocannabinol J. Leukoc. Biol., December 1, 2008; 84(6): 1574 - 1584. [Abstract] [Full Text] [PDF]

				J. P. Buchweitz, P. W. F. Karmaus, K. J. Williams, J. R. Harkema, and N. E. Kaminski Targeted deletion of cannabinoid receptors CB1 and CB2 produced enhanced inflammatory responses to influenza A/PR/8/34 in the absence and presence of {Delta}9-tetrahydrocannabinol J. Leukoc. Biol., March 1, 2008; 83(3): 785 - 796. [Abstract] [Full Text] [PDF]

				R. Ramer and B. Hinz Inhibition of Cancer Cell Invasion by Cannabinoids via Increased Expression of Tissue Inhibitor of Matrix Metalloproteinases-1 J Natl Cancer Inst, January 2, 2008; 100(1): 59 - 69. [Abstract] [Full Text] [PDF]

				N. Joshi, L. L. Johnson, W.-Q. Wei, C. C. Abnet, Z.-W. Dong, P. R. Taylor, P. J. Limburg, S. M. Dawsey, E. T. Hawk, Y.-L. Qiao, et al. Gene Expression Differences in Normal Esophageal Mucosa Associated with Regression and Progression of Mild and Moderate Squamous Dysplasia in a High-Risk Chinese Population. Cancer Res., July 1, 2006; 66(13): 6851 - 6860. [Abstract] [Full Text] [PDF]

				C. E. Rockwell, N. T. Snider, J. T. Thompson, J. P. Vanden Heuvel, and N. E. Kaminski Interleukin-2 Suppression by 2-Arachidonyl Glycerol Is Mediated through Peroxisome Proliferator-Activated Receptor {gamma} Independently of Cannabinoid Receptors 1 and 2 Mol. Pharmacol., July 1, 2006; 70(1): 101 - 111. [Abstract] [Full Text] [PDF]

				S. Raduner, A. Majewska, J.-Z. Chen, X.-Q. Xie, J. Hamon, B. Faller, K.-H. Altmann, and J. Gertsch Alkylamides from Echinacea Are a New Class of Cannabinomimetics: CANNABINOID TYPE 2 RECEPTOR-DEPENDENT AND -INDEPENDENT IMMUNOMODULATORY EFFECTS J. Biol. Chem., May 19, 2006; 281(20): 14192 - 14206. [Abstract] [Full Text] [PDF]

				G. K. Rao and N. E. Kaminski Cannabinoid-Mediated Elevation of Intracellular Calcium: A Structure-Activity Relationship J. Pharmacol. Exp. Ther., May 1, 2006; 317(2): 820 - 829. [Abstract] [Full Text] [PDF]

				C. A. Lunn, J. S. Fine, A. Rojas-Triana, J. V. Jackson, X. Fan, T. T. Kung, W. Gonsiorek, M. A. Schwarz, B. Lavey, J. A. Kozlowski, et al. A Novel Cannabinoid Peripheral Cannabinoid Receptor-Selective Inverse Agonist Blocks Leukocyte Recruitment in Vivo J. Pharmacol. Exp. Ther., February 1, 2006; 316(2): 780 - 788. [Abstract] [Full Text] [PDF]

				G. K. Rao and N. E. Kaminski Induction of intracellular calcium elevation by {Delta}9-tetrahydrocannabinol in T cells involves TRPC1 channels J. Leukoc. Biol., January 1, 2006; 79(1): 202 - 213. [Abstract] [Full Text] [PDF]

				B. L. F. Kaplan, Y. Ouyang, C. E. Rockwell, G. K. Rao, and N. E. Kaminski 2-Arachidonoyl-glycerol suppresses interferon-{gamma} production in phorbol ester/ionomycin-activated mouse splenocytes independent of CB1 or CB2 J. Leukoc. Biol., June 1, 2005; 77(6): 966 - 974. [Abstract] [Full Text] [PDF]

				C. E. Rockwell and N. E. Kaminski A Cyclooxygenase Metabolite of Anandamide Causes Inhibition of Interleukin-2 Secretion in Murine Splenocytes J. Pharmacol. Exp. Ther., November 1, 2004; 311(2): 683 - 690. [Abstract] [Full Text] [PDF]

				G. K. Rao, W. Zhang, and N. E. Kaminski Cannabinoid receptor-mediated regulation of intracellular calcium by {Delta}9-tetrahydrocannabinol in resting T cells J. Leukoc. Biol., May 1, 2004; 75(5): 884 - 892. [Abstract] [Full Text] [PDF]

				P. Massi, A. Vaccani, S. Ceruti, A. Colombo, M. P. Abbracchio, and D. Parolaro Antitumor Effects of Cannabidiol, a Nonpsychoactive Cannabinoid, on Human Glioma Cell Lines J. Pharmacol. Exp. Ther., March 1, 2004; 308(3): 838 - 845. [Abstract] [Full Text] [PDF]